ASH2023 - Sheba 2.0, page-81

What a surprise that the efficacy of Bisantrene matches historic data.

Remember:
1. The dosing protocol for AML is not supportive of long-term FTO inhibition (to have achieved a result like this in patients like this demonstrates the strength of the FTO pathway)
2. Bisantrene far greater FTO inhibitor than anthracycline
3. Efficacy is driven largely by FTO inhibition and drug synergy (evidence-informed personal speculation)
4. No cardiotoxicity at high doses, despite the cardiotoxic profile of Clo and Flo
5. EMD a metastatic extension of AML, driven in part by aberrant FTO expression
6. EMD representing solid-like tumors, thus suggesting efficacy in solid tumor types

As a holder and student of Bisantrene, this outcome is of no surprise to me. Patiently waiting for clinical confirmation of FTO inhibition in humans. If so, it will be a new chapter in oncology. The first ever drug to target a highly conserved modulator of mRNA epitranscriptomics.

Clinical validation of FTO soon, please. This is not a competitor in a crowded space. It's the potential leader of a completely novel, inclusive, complimentary area od oncology.